TY - JOUR T1 - The Use of Procalcitonin as an Antimicrobial Stewardship Tool and a Predictor of Disease Severity in COVID-19 JF - medRxiv DO - 10.1101/2021.01.14.21249853 SP - 2021.01.14.21249853 AU - George P Drewett AU - Olivia C Smibert AU - Natasha E Holmes AU - Jason A Trubiano Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/15/2021.01.14.21249853.abstract N2 - In our study, procalcitonin was associated with both antibiotic use and duration in patients with COVID-19, as well as established biochemical markers of COVID-19 disease severity and oxygen requirement, suggesting a potential role for procalcitonin in COVID-19 antimicrobial stewardship.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Austin Health Human Research and Ethics Committee (database access CD 20002)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata is available by request to corresponding author ER -